Theertha Biopharma joined the global biopharma community at the BIO International Convention — the industry's largest partnering event — presenting from booth 3351‑S on the exhibition floor in San Diego, June 2026.
Across the week our team held partnering meetings with biotech, pharma and investment leaders from the United States, Europe and beyond — introducing Theertha's integrated model: the PepXen™ high‑expression biosimilar platform, HNOVA™ encapsulation technology, plasmid DNA manufacturing, and the EXOMIE™ plant‑derived exosome platform.
A central theme of our conversations was a fast, compliant US/EU‑to‑India bridge for cell & gene therapy — moving a Phase I asset into an India Phase II pathway with a specialised viral‑vector and cell‑therapy partner. The response confirmed strong international appetite for exactly this kind of end‑to‑end, cost‑efficient development partnership.
Met us at BIO, or finding us here first? Start a conversation.